Hepcidin Mimetic
Rusfertide (PTG-300)
Not yet scored
BioHarmony verdict
Awaiting review
No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.
What is Rusfertide (PTG-300)?
Rusfertide is an investigational hepcidin mimetic peptide studied in Phase 3 for polycythemia vera. A completed Phase 2 trial and Phase 3 topline results do not by themselves constitute FDA approval.
Dosing as published
No approved-label or study protocol is recorded for Rusfertide (PTG-300) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
US approvalInvestigational
CompoundingEligibility not established.
Last checked2026-07-13
Next review2026-10-11
Primary sources
- Phase 3 VERIFY study of rusfertide in polycythemia veraClinicalTrials.gov · 2025-08-07
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.